bioAffinity Technologies (BIAFW) Liabilities and Shareholders Equity (2021 - 2026)

bioAffinity Technologies (BIAFW) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $7.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $7.9 million, up 43.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.2 million (up 39.31% YoY), and the FY2025 annual result was $11.0 million, up 68.27% from the prior year.
• Liabilities and Shareholders Equity fell to $7.9 million in Q1 2026 per BIAFW's latest filing, from $11.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $14.1 million in Q3 2022 and troughed at $4.8 million in Q2 2025.
• A 5-year average of $8.8 million and a median of $8.2 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 738.23% in 2022, then plunged 35.7% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $12.2 million in 2022, then plunged by 32.51% to $8.2 million in 2023, then dropped by 20.77% to $6.5 million in 2024, then surged by 68.27% to $11.0 million in 2025, then declined by 27.51% to $7.9 million in 2026.
• Business Quant data shows BIAFW's Liabilities and Shareholders Equity at $7.9 million in Q1 2026, $11.0 million in Q4 2025, and $11.5 million in Q3 2025.